These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 9505878)
1. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Eggleston A; Wigerinck A; Huijghebaert S; Dubois D; Haycox A Gut; 1998 Jan; 42(1):13-6. PubMed ID: 9505878 [TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic gastro-oesophageal reflux disease. Stålhammar NO; Carlsson J; Peacock R; Müller-Lissner S; Bigard MA; Porro GB; Ponce J; Hosie J; Scott M; Weir DG; Fulton C; Gillon K; Bardhan KD Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):483-97. PubMed ID: 10662395 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Hatlebakk JG; Berstad A Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586 [TBL] [Abstract][Full Text] [Related]
4. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery. Myrvold HE; Lundell L; Miettinen P; Pedersen SA; Liedman B; Hatlebakk J; Julkunen R; Levander K; Lamm M; Mattson C; Carlsson J; Ståhlhammar NO; Gut; 2001 Oct; 49(4):488-94. PubMed ID: 11559644 [TBL] [Abstract][Full Text] [Related]
5. A practice-based approach for converting from proton pump inhibitors to less costly therapy. Lucas LM; Gerrity MS; Anderson T Eff Clin Pract; 2001; 4(6):263-70. PubMed ID: 11769299 [TBL] [Abstract][Full Text] [Related]
6. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. Craig AM; Davey P; Malek M; Murray F Pharmacoeconomics; 1996 Jul; 10(1):79-92. PubMed ID: 10160472 [TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. Wahlqvist P; Junghard O; Higgins A; Green J Pharmacoeconomics; 2002; 20(4):267-77. PubMed ID: 11950383 [TBL] [Abstract][Full Text] [Related]
8. The effect of cisapride and ranitidine as monotherapies and in combination in the treatment of uncomplicated gastric ulceration. Stubberöd A; Glise H; Hallerbäck B; Solhaug JH Scand J Gastroenterol; 1995 Feb; 30(2):106-10. PubMed ID: 7732330 [TBL] [Abstract][Full Text] [Related]
9. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Venables TL; Newland RD; Patel AC; Hole J; Wilcock C; Turbitt ML Scand J Gastroenterol; 1997 Oct; 32(10):965-73. PubMed ID: 9361167 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. Remák E; Brown RE; Yuen C; Robinson A Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890 [TBL] [Abstract][Full Text] [Related]
11. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Bardhan KD Aliment Pharmacol Ther; 1995; 9 Suppl 1():15-25. PubMed ID: 7495937 [TBL] [Abstract][Full Text] [Related]
12. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastro-oesophageal reflux. Poynard T; Vernisse B; Agostini H Aliment Pharmacol Ther; 1998 Feb; 12(2):159-65. PubMed ID: 9692690 [TBL] [Abstract][Full Text] [Related]
14. Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease. Hillman AL Scand J Gastroenterol Suppl; 1994; 201():98-102. PubMed ID: 8047833 [TBL] [Abstract][Full Text] [Related]
15. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Hillman AL; Bloom BS; Fendrick AM; Schwartz JS Arch Intern Med; 1992 Jul; 152(7):1467-72. PubMed ID: 1627026 [TBL] [Abstract][Full Text] [Related]
16. Omeprazole or ranitidine plus metoclopramide for patients with severe erosive oesophagitis. A cost-effectiveness analysis. Bloom BS; Hillman AL; LaMont B; Liss C; Schwartz JS; Stever GJ Pharmacoeconomics; 1995 Oct; 8(4):343-9. PubMed ID: 10155675 [TBL] [Abstract][Full Text] [Related]
17. Effect of elimination of acid reflux on epithelial cell proliferative activity of Barrett esophagus. Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Karrenbeld A; de Jager-Krikken A; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH Scand J Gastroenterol; 2000 Dec; 35(12):1238-44. PubMed ID: 11199360 [TBL] [Abstract][Full Text] [Related]
18. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Ofman JJ; Dorn GH; Fennerty MB; Fass R Aliment Pharmacol Ther; 2002 Feb; 16(2):261-73. PubMed ID: 11860409 [TBL] [Abstract][Full Text] [Related]
19. A cost-utility analysis comparing omeprazole with ranitidine in the maintenance therapy of peptic esophageal stricture. Stal JM; Gregor JC; Preiksaitis HG; Reynolds RP Can J Gastroenterol; 1998; 12(1):43-9. PubMed ID: 9544411 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia. Kaplan-Machlis B; Spiegler GE; Zodet MW; Revicki DA Arch Fam Med; 2000 Jul; 9(7):624-30. PubMed ID: 10910310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]